Quarterly report pursuant to Section 13 or 15(d)

Note 9 - Subsequent Events (Details Textual)

v3.23.3
Note 9 - Subsequent Events (Details Textual) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended
Nov. 30, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)   $ 1.55 $ 1.55 $ 1.32 $ 3.3
Subsequent Event [Member] | Series A Warrants Associated with November 2023 Public Offering [Member]          
Class of Warrant or Right, Number of Warrants Per Unit (in shares) 1        
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) 1        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.3006        
Warrants and Rights Outstanding, Term (Year) 5 years        
Subsequent Event [Member] | Series B Warrants Associated with November 2023 Public Offering [Member]          
Class of Warrant or Right, Number of Warrants Per Unit (in shares) 1        
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) 1        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.3006        
Warrants and Rights Outstanding, Term (Year) 18 months        
November 2023 Public Offering [Member] | Subsequent Event [Member]          
Sale of Stock, Number of Units Issued in Transaction (in shares) 16,633,400        
Sale of Stock, Price Per Unit (in dollars per share) $ 0.3006        
Sale of Stock, Number of Shares Per Unit (in shares) 1        
Proceeds from Issuance or Sale of Equity $ 5.0        
Sale of Stock, Consideration Received on Transaction 3.9        
November 2023 Public Offering [Member] | Subsequent Event [Member] | Invagen Pharmaceuticals Inc [Member]          
Sale of Stock, Fees $ 0.3